Market Overview

'Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality,' H.C. Wainwright Says

Share:
'Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality,' H.C. Wainwright Says
Related
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
71 Biggest Movers From Friday

H.C.Wainwright & Co. initiated coverage on Kadmon Holdings Inc (NYSE: KDMN) with a Buy rating and a price tag of $25, citing varied clinical pipeline.

Analysts led by Andrew Fein categorized biotech firms into three sections. The first category belonged to those that have proven track record, whereas the second related to clinical agent/class with a unique MoA. The third category is a de-risked and an established MoA.

"In our view, Kadmon combines the best features of those three categories in one company. First, it has on board many from the old Imclone team, who have done this all before successfully (remember that in biotech people typically perform more reliably than science)," the analysts said.

Related Link: Jefferies Initiates Coverage On Kadmon Holdings At Buy, Announces $12 PT

The brokerage pointed to a few factors that would help the company an advantageous position. For instance, its program on kinase inhibitors has a history of being an active agent in the event of defining the target patient correctly. Secondly, its clinical leads have an advantage of expanding into others even if it meant being successful on any one, i.e., EGFR or ROCK2.

H.C. Wainwright believes Kadmon Holdings has an experienced management, providing value proposition within the biotech spectrum and that the parallel hunt for a number of clinical threads de-risk the company. The lead analyst confidence is that even if the company could achieve success only in a few of these clinical threads, it would be able to reward investors.

On Friday, shares closed at $9.97, down 0.80 percent.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for KDMN

DateFirmActionFromTo
Oct 2017WBB SecuritiesDowngradesHoldSell
Aug 2016H.C. WainwrightInitiates Coverage onBuy
Aug 2016JMP SecuritiesInitiates Coverage onOutperform

View More Analyst Ratings for KDMN
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Initiation Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (KDMN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MDRXKeyBancUpgrades0.0
ANETNomuraUpgrades260.0
CNPRBC CapitalUpgrades34.0
FISVOppenheimerUpgrades88.0
FNDUBSUpgrades37.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Tactile Systems Likely To Expand Sales And Marketing Effort Says BTIG

BTIG Previews Workday's Q2 Results, Comments On IBM Deal